Page 17 - Pharmaceutical Firms

DRL partners with Coya Therapeutics to develop nerve disorder therapy

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurological disorder characterised by progressive degeneration of nerve cells in the spinal cord and brain

Lupin Ltd receives USFDA approval for smoking cessation drug Chantix

The product will be manufactured at Lupin's Pithampur facility in India, the company said in a regulatory filing

Advent International may sell majority stake in Bharat Serums & Vaccines

Global PE major in initial talks with Indian as well as foreign investors

India, US to boost cooperation in pharma, critical minerals & emerging tech

India and the US have agreed to strengthen cooperation in sectors like pharmaceuticals, semiconductors, critical minerals and emerging technologies, an official statement said on Friday. The two countries also discussed collaborative opportunities in green and clean technologies; and strengthening partnership in critical technologies, the commerce ministry said. These key areas emerged from the discussions during the meeting of Commerce and Industry Minister Piyush Goyal and US Secretary of Commerce Gina Raimondo at a review meeting of the India-US CEO Forum virtually last night. "As both sides are focused on closer engagement based on trust, following key areas emerged from the discussions -- supply chain cooperation across pharma, semiconductors, critical minerals and energy; collaborative opportunities in green tech and scaling up manufacturing for clean tech; and strengthening partnership in critical and emerging technologies," it said. Raimondo urged the CEO Forum to seize the

Drug manufacturers in India benefit from Big Pharma interest beyond China

China has for nearly 20 years been the preferred location for a range of pharmaceutical research and manufacturing services due to the low cost and speed offered by contract drugmakers there

Aurobindo Pharma subsidiary receives USFDA approval for Ryzeneuta

It helps to enhance the immune function of cancer patients and prevent the side effects of neutropenia caused by chemotherapy

Pharma company Laurus Labs acquires 87.59% stake in Laurus Bio Private

The acquisition was made through a secondary purchase from the promoter group shareholders of Laurus Bio on November 20, 2023

Cipla's Pithampur unit gets USFDA warning; analysts remain bullish

On Monday, Cipla share price dropped 0.21 per cent, ending the day's trade at Rs 1,246 apiece on the BSE

Industry has potential to grow to $200 bn in value by 2030: Pharma Secy

The domestic pharmaceutical industry has the potential to grow by 4-5 times to around USD 200 billion in value terms by scaling up manufacturing and enhancing exports, a senior government official said on Friday. He noted that to reach a size of USD 200 billion by 2030 from around USD 50 billion currently, the industry needs to grow in double digits year-on-year while reducing dependence on imports and focussing on expanding exports. "The age of smart medicine is dawning upon us. The new therapies that will come to the fore in the next 20 to 30 years would deliver smart therapies virtually for every difficult illness that we know of today. We have to be ready for that age. We have to prepare for that age," Department of Pharmaceuticals Secretary Arunish Chawla said at a CII event here. He said the government is helping the industry with various policy initiatives, including production-linked incentives. "At USD 50 billion in 2020, we were a little over 10 per cent of our manufactur

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

The delayed season not only affected anti-infectives but also related sub-therapies such as respiratory, cough and cold, gastro, and vitamins, says Juneja

Torrent, Zydus collaborate to bring liver disease treatment to India

Saroglitazar Mg received approval in March 2020 for NASH treatment and later expanded its indications to include NAFLD

Novavax plans to slash costs by another $300 mn amid sagging demand

Novavax shares rose 3.1% at 10:26 a.m. in New York after the company's third-quarter loss per share and revenue were better than analysts expected

Glenmark Pharmaceuticals receives USFDA approval for generic Prolixin

Prolixin is a prescription medication used to treat schizophrenia and other mental/mood disorders

Lupin's net profit jumps nearly four-fold on strong US growth, stock up

US sales cross $200 million for the first time in two years, beat analyst expectations

Lupin introduces generic version of Zemuron Injection in United States

The newly introduced Rocuronium Bromide Injection is available in two formulations

Cipla announces transfer of Generics Business Undertaking to subsidiary

The generics business contributed 9.95 per cent of Cipla's turnover and 0.92 per cent of its net worth in the financial year ended March 31, 2023

Alkem Laboratories posts 87.85% increase in PAT, sales in India up by 5%

On a sequential basis, the company exhibited a 16.26 per cent increase in revenue

Should touch Rs 1K crore from OTC this year, says Nandini Piramal

The benefit of having patented products contract manufacturing is that there is always growth, said Piramal

Gland Pharma Q2 result: Net profit fell 20% to Rs 194 cr on higher expenses

Gland Pharma reported a nearly 32% jump in revenue from operations to Rs 1,373 crore, driven by higher sales from the acquisition of the French pharmaceutical group Cenexi in January

Sun Pharmaceutical's vital signs: A strong dose of valuation multiples

The specialty segment and domestic business act as the lifeblood, coursing through the largest pharma company in the country, fuelling both revenue and margins